Erik Magnus Ohman, MBBS

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 8678A Hafs Bldg, Durham, NC 27710
Phone (919) 681-2069
Email address ohman001@mc.duke.edu

Dr. Ohman, Professor of Medicine, received medical degrees from the Royal College of Surgeons in Ireland and the National University of Ireland (1984, Fellowship 1984-1987), and completed his training in cardiology at Duke University (1987-1991), where he has remained on faculty. In 2001, he became Chief of Cardiology at the University of North Carolina at Chapel Hill, where he founded the UNC Heart Center and became its first director. In 2005 he returned to Duke to pursue his interest in advanced coronary disease as the Director of the Program for Advanced Coronary Disease. Since that time, he has been appointed to Associate Director of the Duke Heart Center, the Kent and Siri Rawson Director for the Program for Advanced Coronary Disease, and most recently, Vice-Chair of Development and Innovation in the Department of Medicine.

Dr. Ohman’s clinical and research interests include interventional cardiology and high-risk supported PCI, and treatment of patients with advanced/complex coronary disease. He has researched how to improve patient care through the use of guidelines-based therapies and adherence, and examining global cardiovascular risk and health. He has been a participant on numerous guidelines writing committees, served on the ACC/AHA oversight committee for guidelines development, and has served on the steering committees for trials on ST-elevation myocardial infarction and non-ST-elevation ACS. He is a consultant to the National Institutes of Health, and a consultant for the FDA Advisory Panel for Cardiovascular Devices. 

Dr. Ohman has published over 600 peer-reviewed papers and three books in cardiovascular medicine. He holds three U.S. patents in reperfusion therapy. He is an associate editor for the American Heart Journal and serves on the editorial boards of the Journal of the American College of Cardiology and the American Journal of Cardiology.  He is a Fellow of the Royal College of Physicians in Ireland, the Royal Society of Medicine (U.K.), the European Society of Cardiology, the Society of Cardiac Angiography and Interventions, and the American College of Cardiology. 

Education and Training

  • M.B.B.S., Royal College of Surgeons (Ireland), 1981

Publications

Granger, C. B., J. M. Miller, E. G. Bovill, A. Gruber, R. P. Tracy, M. W. Krucoff, C. Green, E. Berrios, R. A. Harrington, and E. M. Ohman. “Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes..” Circulation 91, no. 7 (April 1, 1995): 1929–35.

PMID
7895349
Scholars@Duke

Armstrong, B., J. P. Zidar, and E. M. Ohman. “The use of intraaortic balloon counterpulsation in acute myocardial infarction and high risk coronary angioplasty..” J Interv Cardiol 8, no. 2 (April 1995): 185–91.

PMID
10155228
Scholars@Duke

Jurlander, B., P. M. Clemmensen, E. M. Ohman, G. S. Wagner, and P. Grande. “[Serum myoglobin as a non-invasive marker of coronary reperfusion after intravenous thrombolytic therapy in patients with acute myocardial infarction]..” Ugeskr Laeger 157, no. 4 (January 23, 1995): 440–43.

PMID
7846789
Scholars@Duke

Christenson, R. H., E. M. Ohman, E. J. Topol, M. A. O’Hanesian, K. N. Sigmon, S. H. Duh -, D. Kereiakes, et al. “Creatine kinase MM and MB isoforms in patients receiving thrombolytic therapy and acute angiography.” Clinical Chemistry 41, no. 6 (January 1, 1995): 844–52.

Scholars@Duke

Phillips, H. R., E. M. Ohman, M. Labinaz, M. H. Sketch, and R. Stack. “Use of the perfusion balloon as a primary dilation device..” J Invasive Cardiol 7 Suppl B (1995): 17B-24B.

PMID
10155119
Scholars@Duke

Kereiakes, D. J., M. H. Sketch, and E. M. Ohman. “Perfusion balloon angioplasty in patients with complex coronary lesion morphology..” J Invasive Cardiol 7 Suppl B (1995): 4B-9B.

PMID
10155123
Scholars@Duke

Granger, C. B., H. D. White, E. R. Bates, E. M. Ohman, and R. M. Califf. “A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction..” Am J Cardiol 74, no. 12 (December 15, 1994): 1220–28.

PMID
7977094
Scholars@Duke

Kleiman, N. S., H. D. White, E. M. Ohman, A. M. Ross, L. H. Woodlief, R. M. Califf, D. R. Holmes, E. Bates, M. Pfisterer, and A. Vahanian. “Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries..” Circulation 90, no. 6 (December 1994): 2658–65.

PMID
7994805
Scholars@Duke

Kleiman, N. S., H. D. White, E. M. Ohman, A. M. Ross, L. H. Woodlief, R. M. Califf, D. R. Holmes, et al. “Mortality within 24 hours of thrombolysis for myocardial infarction: The importance of early reperfusion.” Circulation 90, no. 6 (December 1, 1994): 2658–65.

Scholars@Duke

Pages